CureVac N.V. (NASDAQ:CVAC) Q4 2022 Earnings Call Transcript

Pierre Kemula: Sure, I can comment. So basically, they can choose and not for any target they want, right? So outside of certain targets, which are both saved by the stuff like that or other targets that we have kept to ourselves. But typically, they can — within that restriction, they can up to any target until the very last moment of the collaboration.

Roy Buchanan: Okay, great. But any sense of the stages of development you can give us, probably not?

Pierre Kemula: No, sorry .

Roy Buchanan: Okay. All right. I guess, just long-term, can you give us the best guess on when you think you can be on market for flu and COVID? And again, I realize you have a partner in this. And then the last question, just the Bill & Melinda Gates candidates, rotavirus, malaria, universal flu, just any idea when those might be in the clinic? Thanks.

Alexander Zehnder: Okay. So two questions. One on time lines for potential approvals for flu and COVID, and a question — follow-up question on the programs within Bill & Melinda Gates.

Pierre Kemula: I can take the BMGF question, if you want here. So, you’re right — you’re right, Roy, there is a set of indications, which we are working on with the Gates Foundation. Today, I guess the work is actually pretty early in preclinical, so difficult for me to give any guidance in terms of clinical timeline. There’s a lot of science being worked on quite cutting-edge science, but that’s not quite yet ready for the clinic.

Pierre Kemula: Right. And regarding the question on — I think it was about when it could be launch or with the flu and or COVID vaccines come to the market again. We — hard to comment right now because the Phase 1 and 2 trials are basically about to start. And so we will sort of like give better projections as the trials are progressing and again, don’t want to disclose right now.

Roy Buchanan: Okay. Thank you.

Operator: We have no further questions at this time. I would now like to turn the floor back over to management for closing comments.

Sarah Fakih: With this, we would like to conclude this conference call. Thank you very much for your participation. Stay safe, and please don’t hesitate to contact us should you have any further questions. Thank you, and goodbye.

Operator: Ladies and gentlemen, this does conclude today’s teleconference. You may disconnect your lines at this time. Thank you for your participation, and have a wonderful day.